Literature DB >> 23122929

Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.

Xue-feng Jiang1, Qiong-lan Tang, Xi-ming Shen, Hai-gang Li, Lun-hua Chen, Xiao-yu Wang, Xin Luo, Zhong-qiu Lin, Guang-yu Jiang.   

Abstract

It has been well established that tumor-associated macrophages (TAMs) play a tumor-promoting role in endometrial endometrioid adenocarcinoma (EEC). However, the association with TAMs and the triple-negative phenotype (TNP) in EEC has not yet been reported. We used immunohistochemistry to examine the expression of CD68, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR) in 186 cases of EEC. Fluorescent in situ hybridization (FISH) was also used for HER2 amplification, and the association with TAMs count, EGFR expression, and triple-negative phenotype was analyzed. Twenty-eight of 186 patients (15.05%) had the TNP. It was associated with advanced stage disease (P<0.0001), high grade disease (P<0.0001), depth of myometrial invasion (P=0.003), pelvic lymph node metastasis (P<0.001), lymphovascular space invasion (P=0.001), and EGFR expression (P=0.032). Margin TAMs count was also significantly increased in the TNP-positive group, the EGFR-positive group, and the PR-negative group (P<0.001, respectively). The TNP was associated with a significantly worse overall survival (OS) (log rank test, P=0.018). The estimated 5-year OS of patients with TNP was 59.1%, while that without TNP was 78.5%. Multivariate analysis showed high margin TAMs, and the histopathological grades were significantly associated with OS. The TNP in EEC is associated with poor prognostic surgical-pathological factors, worse prognosis, as well as with high margin TAMs and overexpression of EGFR, which may serve as potential targeted therapies for the special phenotype in EEC.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23122929     DOI: 10.1016/j.prp.2012.09.011

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  6 in total

Review 1.  Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.

Authors:  Umar Mehraj; Hina Qayoom; Manzoor A Mir
Journal:  Breast Cancer       Date:  2021-03-04       Impact factor: 4.239

2.  Tissue Infiltrating Immune Cells as Prognostic Biomarkers in Endometrial Cancer: A Meta-Analysis.

Authors:  Fang Guo; Yishan Dong; Qingqing Tan; Jing Kong; Bin Yu
Journal:  Dis Markers       Date:  2020-01-28       Impact factor: 3.434

3.  Triple negative endometrial cancer: Incidence and prognosis in a monoinstitutional series of 220 patients.

Authors:  Rosa Porzio; Claudia Cordini; Anna Maria Rodolfi; Francesca Brigati; Alessandro Ubiali; Manuela Proietto; Camilla Di Nunzio; Luigi Cavanna
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

4.  HER2-positive endometrial cancer subtype carries poor prognosis.

Authors:  Sylwia Lapińska-Szumczyk; Anna Supernat; Hanna Majewska; Jacek Gulczyński; Agata Luczak; Wojciech Biernat; Dariusz Wydra; Anna J Zaczek
Journal:  Clin Transl Sci       Date:  2014-09-09       Impact factor: 4.689

Review 5.  New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy.

Authors:  Qiujun Guo; Zhichao Jin; Yuan Yuan; Rui Liu; Tao Xu; Huamin Wei; Xinyao Xu; Shulin He; Shuntai Chen; Zhan Shi; Wei Hou; Baojin Hua
Journal:  J Immunol Res       Date:  2016-11-16       Impact factor: 4.818

Review 6.  "Iron triangle" of regulating the uterine microecology: Endometrial microbiota, immunity and endometrium.

Authors:  Na Zhu; Xuyan Yang; Qiao Liu; Yahui Chen; Xiaolan Wang; Huanhuan Li; Hong Gao
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.